Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10598361 | Bioorganic & Medicinal Chemistry Letters | 2005 | 5 Pages |
Abstract
Herein we describe a series of potent and selective PPARγ agonists with moderate PPARα affinity and little to no affinity for other nuclear receptors. In vivo studies in a NIDDM animal model (ZDF rat) showed that these compounds are efficacious at low doses in glucose normalization and plasma triglyceride reduction. Compound 1b (LY519818) was selected from our SAR studies to be advanced to clinical evaluation for the treatment of type II diabetes.
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
José A. MartÃn, Dawn A. Brooks, Lourdes Prieto, Rosario González, Alicia Torrado, Isabel Rojo, Beatriz López de Uralde, Carlos Lamas, Rafael Ferritto, MarÃa Dolores MartÃn-Ortega, Javier Agejas, Francisco Parra, John R. Rizzo, Gary A. Rhodes,